Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Juan Francisco Guerra is active.

Publication


Featured researches published by Juan Francisco Guerra.


Transplantation Proceedings | 2010

Liver Transplantation Results for Hepatocellular Carcinoma in Chile

M. Gabrielli; M. Vivanco; J. Hepp; Jorge Martínez; Rosa María Pérez; Juan Francisco Guerra; Marco Arrese; E. Figueroa; A. Soza; R. Yáñes; R. Humeres; H. Rios; J.M. Palacios; R. Zapata; E. Sanhueza; J. Contreras; G. Rencoret; R. Rossi; Nicolás Jarufe

UNLABELLED Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Liver transplantation is the best treatment for HCC; it improves survival, cures cirrhosis, and abolishes local recurrence. We describe the outcomes of patients with HCC who underwent liver transplantation in two liver transplantation centers in Chile. METHODS This study is a clinical series elaborated from the liver transplantation database of Pontificia Universidad Católica and Clínica Alemana between 1993 and 2009. The survival of patients was calculated using the Kaplan-Meier survival analysis. The significant alpha level was defined as <.05. RESULTS From 250 liver transplantations performed in this period, 29 were due to HCC. At the end of the study, 25 patients (86%) were alive. The mean recurrence-free survival was 30 months (range 5 months to 8 years). The 5-year survival for patients transplanted for HCC was >80%; however, the 5-year overall survival of patients who exceeded the Milan criteria in the explants was 66%. There was no difference in overall survival between patients transplanted for HCC versus other diagnosis (P = .548). CONCLUSION This series confirmed that liver transplantation is a good treatment for patients with HCC within the Milan criteria.


Revista Medica De Chile | 2008

Complicaciones neurológicas en pacientes adultos sometidos a trasplante hepático ortotópico: Experiencia de un centro universitario

Patricio Mellado; Pilar Peredo; Raúl Valenzuela; Marco Arrese; Rosa María Pérez; Pilar Domínguez; Juan Francisco Guerra; Nicolás Jarufe; Jorge Martínez

BACKGROUND Orthotopic liver transplantation (OLT) is the treatment of choice for multiple acute and chronic end-stage liver diseases as well as for selected cases of liver malignancy and liver-site metabolic disorders. Neurological impairment is a major source of morbidity and mortality following OLT. AIM To describe the incidence and the type of neurological complications occurring in the post-operative period of OLT in patients transplanted in our hospital. MATERIAL AND METHODS Between March 1994 and August 2007, 76 adult patients underwent OLT. Data on incidence, time of onset, and outcome of central nervous system (CNS) complications have been obtained from our program data base and patient charts. RESULTS Twenty three patients (30.3%) had CNS complications following OLT. The leading complications were immunosuppressive drug-related neurological impairment in nine patients (39.1%), peripheral nerve damage in five patients (21.7%), central pontine myelinolysis in four patients (17.4%), cerebrovascular disease in three (13%) and CNS infection in three (13%). Most CNS events (90%) occurred in the first 2 weeks after OLT. Five patients with neurological complications died (22%). CONCLUSIONS CNS complications occurred in almost one fifth of the population studied, and they had a poor outcome, as previously reported).


Alimentary Pharmacology & Therapeutics | 2017

Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study

S. Solari; A. Cancino; R. Wolff; Blanca Norero; Jose Ignacio Vargas; Francisco Barrera; Juan Francisco Guerra; Jorge Martínez; Nicolás Jarufe; Alejandro Soza; Marco Arrese; Carlos Benítez

Per‐oral tacrolimus administration is not always practicable. Sublingual administration is a potential alternative, but its feasibility and effectiveness compared with oral route has not been established.


World Journal of Surgical Oncology | 2013

Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases

José Galindo; Mauricio Gabrielli; Juan Francisco Guerra; Juan Carlos Cassina; Marcelo Garrido; Nicolás Jarufe; Yerko Borghero; Jorge Madrid; Pablo Zoroquiain; Juan Carlos Roa; Jorge Martínez

Pancreatic cancer remains as one of the most aggressive human neoplasms, with overall poor survival rates. Radical surgery of the primary lesion is the best option for treatment. Borderline resectable pancreatic tumors (BRPT), defined as partial involvement of peripancreatic vasculature, may benefit from neoadjuvant therapy. We report on the first two BRPT cases treated with neoadjuvant chemoradiation at our institution. Preoperative CT and MRI demonstrated pancreatic tumors encasing the porto-mesenteric confluence suggestive of BRPT. Patients received neoadjuvant chemotherapy (gemcitabine/cisplatin), followed by radiochemotherapy. After treatment, follow-up images demonstrated tumor downsize, allowing for the tumors to be considered then as resectable. They underwent partial pancreatoduodenectomies (Whipple procedure). In case 1, histopathology revealed a complete, margin-free resection, whereas in case 2 there was a complete pathological response, with no evidence of residual tumor. According to the literature, our initial experience using neoadjuvant chemoradiotherapy on BRPT allowed us to downsize the tumor and, subsequently, to perform a curative surgery.


Revista Medica De Chile | 2009

Resultados del tratamiento quirúrgico de las metástasis hepáticas por cáncer colorrectal

Enrique Norero; Nicolás Jarufe; Jean Michel Butte; Blanca Norero; Ignacio Duarte; Javiera Torres; George Pinedo; Francisco López; Juan Francisco Guerra; Luis Ibáñez; Álvaro Zúñiga; Sergio Guzmán; Jorge Martínez

Background: Surgical resection is the only treatment associated with long-term cure in patients with liver metastasis from colorectal cancer, achieving a 30% to 40% five years survival. Aim: To evaluate the results of liver resection for metastatic colorectal cancer in our centre. Patients and methods: Retrospective study. Epidemiological, perioperative and follow up data of patients undergoing liver resection for metastatic colorectal cancer between January 1990 and July 2007 were assessed. We compared the results between two periods; period 1 (1990-1997) and period 2 (1998-2007). Results: Sixty six patients aged 61±12 years (46 males) underwent 75 resections. An anatomical excision was performed in 54 (72%) cases, a right hepatectomy in 18, an extended right hepatectomy in 11, a left hepatectomy in 1, and a segmentectomy in 24. In 24 (32%) patients the liver resection was simultaneous with the colorectal cancer resection. Operative time was 221±86 min. Hospital stay was 11±5 days. Postoperative morbidity was 35% and surgical mortality was 0%. Resection margin was free of tumor in 53 (80%) patients. Five years overall and hepatic disease-free survival was 38% and 23%, respectively. In period 2, more anatomical resections than in period 1 were performed (77% and 55%, respectively, p =0.04), without an increase in complications (35% and 34%, respectively; p =ns), but with a better five years survival (45% and 21%, respectively, p =0.04). Conclusions: Five years survival for excision of liver metastatic colorectal cancer in our center is similar to that reported abroad. During the second period there has been a trend toward more extensive resections which was associated with a better survival, without an increase in complications or mortality (Rev Med Chile 2009; 137: 487-96). (Key words: Colorectal neoplasms; Neoplasm metastasis; Survival)


International Journal of Surgery Case Reports | 2015

Emergency right hepatectomy after laparoscopic tru-cut liver biopsy

Nicolás Quezada; Felipe León; Jorge Martínez; Nicolás Jarufe; Juan Francisco Guerra

Highlights • Tru-cut liver biopsy is a common diagnostic procedure for many liver diseases.• Bleeding following tru-cut liver biopsies is uncommon.• Emergency hepatectomy due to hemorrhage following tru-cut liver biopsies is exceptional.


Transplantation Proceedings | 2010

Bridge Therapy in Hepatocellular Carcinoma Before Liver Transplantation: The Experience of Two Chilean Centers

M. Vivanco; M. Gabrielli; Nicolás Jarufe; R. Humeres; H. Rios; J.M. Palacios; R. Zapata; E. Sanhueza; J. Contreras; G. Rencore; R. Rossi; Jorge Martínez; R. Pérez; Juan Francisco Guerra; Marco Arrese; E. Figueroa; A. Soza; R. Yáñes; Juan Hepp

BACKGROUND Orthotopic liver transplantation (OLT) is currently an established therapy for small, early-stage hepatocellular carcinoma (HCC) within the Milan criteria. Long waiting times due to the shortage of donor organs can result in tumor progression and drop-out from OLT candidacy. Therefore a wide variety of procedures are necessary before OLT. The aim of this retrospective study was to review our experience in relation to bridge therapy prior to OLT for HCC. METHODS This was a retrospective database review of all of the patient who underwent transplantation in our institutions between January 1993 and June 2009. We analyzed patients with a diagnosis of HCC in the explant. RESULTS Among 29 patients, including 12 who were diagnosed by the explant and 17 prior to transplantation, 88% underwent bridge therapy during a mean waiting time to OLT of 12 months. Among the 23 procedures, namely 1.5 procedures per patient, included most frequently chemoembolization (48%), alcohol ablation (30%), radiofrequency ablation (13%), and surgery (9%). Thirty-three percent of the explants contained lesions within the Milan criteria. In our series the 5-year survival rate for patients transplanted for HCC was 86%; in the bridge therapy group, it was 73%. CONCLUSIONS The incidence of patients who underwent bridge therapy (52%) was similar to other reported experiences, but the fulfillment of Milan criteria in the explants was lower. Among the bridge therapy group, the survival was slightly lower, probably because this group displayed more advanced disease.


Revista Medica De Chile | 2016

Insuficiencia intestinal secundaria a síndrome de intestino corto: resultados de un programa multidisciplinario de rehabilitación intestinal

María Elena Molina; Felipe Bellolio; Julieta Klaassen; Javier Gómez; Constanza Villalón; Juan Francisco Guerra; Álvaro Zúñiga

BACKGROUND In patients suffering intestinal failure due to short bowel, the goal of an Intestinal Rehabilitation Program is to optimize and tailor all aspects of clinical management, and eventually, wean patients off lifelong parenteral nutrition. AIM To report the results of our program in patients suffering intestinal failure. PATIENTS AND METHODS A registry of all patients referred to the Intestinal Failure unit between January 2009 and December 2015 was constructed. Initial work up included prior intestinal surgery, blood tests, endoscopic and imaging studies. Also demographic data, medical and surgical management as well as clinical follow-up, were registered. RESULTS Data from 14 consecutive patients aged 26 to 84 years (13 women) was reviewed. Mean length of remnant small bowel was 100 cm and they were on parenteral nutrition for a median of eight months. Seven of 14 patients had short bowel secondary to mesenteric vascular events (embolism/thrombosis). Medical management and autologous reconstruction of the bowel included jejuno-colic anastomosis in six, enterorraphies in three, entero-rectal anastomosis in two, lengthening procedures in two, ileo-colic anastomosis in one and reversal Roux-Y gastric bypass in one. Thirteen of 14 patients were weaned off parenteral nutrition. CONCLUSIONS Our Multidisciplinary Intestinal Rehabilitation Program, allowed weaning most of the studied patients off parenteral nutrition.Background: In patients suffering intestinal failure due to short bowel, the goal of an Intestinal Rehabilitation Program is to optimize and tailor all aspects of clinical management, and eventually, wean patients off lifelong parenteral nutrition. Aim: To report the results of our program in patients suffering intestinal failure. Patients and methods: A registry of all patients referred to the Intestinal Failure unit between January 2009 and December 2015 was constructed. Initial work up included prior intestinal surgery, blood tests, endoscopic and imaging studies. Also demographic data, medical and surgical management as well as clinical follow-up, were registered. Results: Data from 14 consecutive patients aged 26 to 84 years (13 women) was reviewed. Mean length of remnant small bowel was 100 cm and they were on parenteral nutrition for a median of eight months. Seven of 14 patients had short bowel secondary to mesenteric vascular events (embolism/thrombosis). Medical management and autologous reconstruction of the bowel included jejuno-colic anastomosis in six, enterorraphies in three, entero-rectal anastomosis in two, lengthening procedures in two, ileo-colic anastomosis in one and reversal Roux-Y gastric bypass in one. Thirteen of 14 patients were weaned off parenteral nutrition. Conclusions: Our Multidisciplinary Intestinal Rehabilitation Program, allowed weaning most of the studied patients off parenteral nutrition.


Revista Medica De Chile | 2014

¿Influye el medio de preservación del injerto en los resultados y costos del trasplante hepático de donante fallecido?: Comparación de dos soluciones de preservación

Jorge Martínez; Jean Phillipe Bächler; Fabrizio Moisan; Javiera Torres; Ignacio Duarte; Rosa María Pérez; Carlos Benítez; Marco Arrese; Pilar Domínguez; Juan Francisco Guerra; Nicolás Jarufe

Preservation solutions are critical for organ transplantation. In liver transplant (LT), the solution developed by the University Of Wisconsin (UW) is the gold-standard to perfuse deceased brain death donor (DBD) grafts. Histidine-Tryptophan-Ketoglutarate (HTK), formerly a cardioplegic infusion, has been also used in solid organ transplantation. Aim: To compare the outcomes of LT in our center using either HTK or UW solution. Patients and Methods: Retrospective study including 93 LT DBD liver grafts in 89 patients transplanted between March 1994 and July 2010. Forty-eight grafts were preserved with UW and 45 with HTK. Donor and recipient demographics, total infused volume, cold ischemia time, post-reperfusion biopsy, liver function tests, incidence of biliary complications, acute rejection and 12-month graft and patient survival were assessed. Preservation solution costs per liver graft were also recorded. Results: Donor and recipient demographics were similar. When comparing UW and HTK, no differences were observed in cold ischemia time (9.6 ± 3 and 8.7 ± 2 h respectively, p = 0.23), biliary complications, the incidence of acute rejection, primary or delayed graft dysfunction. Histology on post-reperfusion biopsies revealed no differences between groups. The infused volume was significantly higher with HTK than with UW (9 (5-16) and 6 (3-11) l, p < 0.001). The cost per procurement was remarkably lower using HTK. Conclusions: Perfusion of DBD liver grafts with HTK is clinically equivalent to UW, with a significant cost reduction


Transplantation Proceedings | 2009

Hepatic Resection After Liver Transplantation as a Graft-Saving Procedure

Juan Francisco Guerra; Nicolás Jarufe; Jorge Martínez

Biliary lesions and hepatic artery thrombosis are known causes of posttransplant liver failure and liver retransplantation. The shortage of organs and the results of retransplantation have forced transplant teams to developed graft-saving techniques. We report two cases who underwent hepatic resection after liver transplantation. In both cases, a left lateral segmentectomy was performed. At follow-up, the patients are well with optimal graft function. We believe this kind of resection represents an adequate alternative in selected cases and must be considered before enlistment for retransplantation.

Collaboration


Dive into the Juan Francisco Guerra's collaboration.

Top Co-Authors

Avatar

Jorge Martínez

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

Nicolás Jarufe

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

Marco Arrese

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

Pablo Achurra

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

Rolando Rebolledo

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

Carlos Benítez

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

Eduardo Briceño

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

J. Saez

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

Javiera Torres

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

Sergio Pacheco

Pontifical Catholic University of Chile

View shared research outputs
Researchain Logo
Decentralizing Knowledge